STARTING NOVEMBER 12th, 2019-2020
Tool antibodies are the dominant affinity reagent for proteomics in cell biology, reflected by the over 4.5 million antibodies that are commercially available. Distinct from therapeutics or diagnostics, tool antibodies tend to be poorly characterized. This is echoed by many reports of catastrophic specificity, activity, identity and reporting deficits involving such reagents.
In this 9-part series, aimed especially at those beginning a career in biological sciences, The Antibody Society has invited leaders in antibody research from industry and academia to reflect on antibody validation. They paint a uniformly alarming picture of inadequacies at many levels – which encourages users to be highly aware of the consequences of inadequate tool antibody validation, which threaten their biological endeavors.
Are you interested in learn how to validate your antibody?
EuroMAbNet has published an article and created easily followed "Guidelines" that provide a set of criteria and recommendations that will help you to select the most effective mAbs from those available in the market and provide the strategic guidance needed to perform any essential antibody validation.
EuroMAbNet represents the first European network of laboratories linked to academic Institutions, each having an internationally recognized reputation in the production and use of monoclonal antibodies.
EuroMAbNet provide an arena in which people working in the field of monoclonal antibody production and technology can exchange knowledge, share the most up-to-date methodology and create common strategies to both standardize and improve the production of properly validated monoclonal antibodies.
EuroMAbNet has recently published a position paper, and Ab validation guidelines providing criteria and recommendations aimed at helping researchers to select the most effective mAbs from those available in the market, and the guidance needed to perform effective antibody validation.